COVID nemite US para Remdesivir manishe

October 23, 2020. Thursday din te U.S. regulators para COVID-19 bemar elaj koribo nemite first tawai approved korishe. Etu tawai toh California-based Gilead Sciences Inc. para Veklury nam thishe aro etu para 5 din pithor te bhal koribo nahoile average to 10 din aro 15 pithor te hobo. Etu tangor study kora toh U.S. National Institutes of Health para loikena korishe. Tawai toh emergency samai joboli authorized korishe aro etu first tawai thakiboli ke Food aro Drug Administration para COVID-19 elaj samai approved kora hobo. President Donald Trump be etu moina bemar howa samai kelaishe. Veklury approved kora toh 12 saal umer manuh 88 pounds (40 kilograms) kaun khan coronavirus bemar nemite. Bemari manuh 12 umer pithor khan ke toh FDA para tawai joboli nemite konuba cases te  emergency authorization pithor te hobo. Etu tawai nalowa agae te kidney aro liver tests loi, keli koile safety aro eku side effects nahobo nemite.  Aro etu toh malaria tawai hydroxychloroquine logot naloboli koishe. “etai ami khan logot knowledge ase aro saman thaka nemite COVID-19 logot larai koriboli parehbo,” koikena Gilead laga chief medical officer, Dr. Merdad Parsey para statement te koishe. Aro etu tawai toh approved korishe nahoile temporary authorization nemite 50 desh te thikena ase. Jaa hafta te, World Health Organization para loikena tangor study kora samai, tawai para hospital te COVID-19 bemar manuh khan logot motob kora nai koishe, study te placebo group khan samil kora nai, hoilebi, agae din te toh motob thakishe. FDA laga approval statement para koishe ke, NIH-led one te dosura tuita tawai be bhal thakishe koishe.